Postgrad LIVE! Study Fairs

Birmingham | Edinburgh | Liverpool | Sheffield | Southampton | Bristol

University of Bristol Featured PhD Programmes
University of Portsmouth Featured PhD Programmes
University of Glasgow Featured PhD Programmes
King’s College London Featured PhD Programmes
Max Planck Society Featured PhD Programmes
"brain" AND "tumour"×
10 miles

brain tumour PhD Projects, Programs & Scholarships

We have 9 brain tumour PhD Projects, Programs & Scholarships

  • "brain" AND "tumour" ×
  • clear all
Order by 
Showing 1 to 9 of 9
  PhD in Cancer Research - Targeting neuroinflammation in mTORC1-driven brain tumours
  Dr A Tee, Prof A Harwood
Application Deadline: 28 February 2019
This project will not only create a new brain tumour model, but will also give us valuable information on mTOR’s involvement in the development of brain tumours.
  MRC DiMeN Doctoral Training Partnership: Harnessing T cells to target brain metastases
  Dr M Lorger, Dr R Salmond, Prof J Newton-Bishop
Application Deadline: 21 January 2019
An MRC-funded PhD student position is available to explore how T cells can be harnessed to enhance the efficacy of immune checkpoint inhibitors in melanoma brain metastases.
  Understanding the molecular mechanisms which drive brain cancer recurrence and defining novel therapies to target these aggressive tumour cell populations
  Dr B Day
Application Deadline: 30 April 2019
Glioblastoma (GBM) is the most common and aggressive adult primary brain cancer. Median survival is. As part of the QIMR-Berghofer Brain Cancer Tissue Bank, we have collected a series of patient specimens which include primary tumours that have not undergone treatment and matching post-treatment recurrent tumours.
  MRC DiMeN Doctoral Training Partnership: Development and application of fast Magnetic Resonance Spectroscopic Imaging methods for neuro-chemical profiling
  Prof J Schneider, Dr S Short
Application Deadline: 21 January 2019
While Magnetic Resonance Imaging is well established to assess anatomy, structure and function in patients and in animal models of human disease alike, (routine) MR Spectroscopy tools to investigate metabolic alterations are far less common.
  Breaking the HGF-cMET axis in medulloblastoma: development of small non-sugar glycosaminoglycan (GAG) mimics as anti-metastatic drugs.
  Dr G Di Leva
Applications accepted all year round
Medulloblastoma (MB) is the most common malignant paediatric brain tumour accounting for about 20% of all childhood brain cancers.
  Development of novel inhibitors for the treatment of Glioblastomas
  Dr S Ahmed, Dr S Darby
Applications accepted all year round
Glioblastoma (GBM) is the most common form of brain tumour in adults and is incurable. Despite optimal treatment consisting of surgery, chemotherapy and radiotherapy, median survival is 15 month.
  How does amino acid metabolism affect tumour growth?
  Dr L. Cheng
Applications accepted all year round
The effect of diet on tumour growth is hotly debated but poorly characterized. Due to the heterogeneous nature of the tumours, dietary studies in patients with varied genetic background often led to inconclusive outcome.
  MRC Precision Medicine DTP: Quantitative proteomic analysis of dysregulated adhesion protein localisation in patient-derived cancer cells
  Research Group: Edinburgh Cancer Research Centre
  Dr A Byron, Prof M Frame, Prof R Zubarev, Dr A Sims
Application Deadline: 7 January 2019
Summary. This project seeks to use proteomic data and computational approaches to identify signatures of cell adhesion proteins that are mislocalised in cells from brain cancer patients.
  Prodrugs Activated by Tumour Microenvironment
  Research Group: Institute of Cancer Therapeutics
  Dr R Wheelhouse, Prof P Loadman, Prof R M Phillips
Applications accepted all year round
The anticancer drug temozolomide (TMZ), has been in the clinic for treating brain tumours for nearly 30 years. Despite its “Blockbuster” status, no other compounds of this class have reached clinical trial.
Show 10 15 30 per page
  • 1

FindAPhD. Copyright 2005-2018
All rights reserved.